Matthias Muenks
Matthias Muenks, Global Engineering Process and Data Manager at Boehringer Ingelheim, speaks about the pharmaceutical company’s innovation and culture.
Search
Media Overview
Media Overview
PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
Learning and development
We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Prescription Digital Therapeutics a New Frontier in Mental Health Care
Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.
Oncology & Cancer Immunology
Oncology & Cancer Immunology
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
Reducing Stress in Horses – With Music
Click here to read more on the release of the Boehringer Ingelheim specially composed music track, designed to keep horses safe and "sound".
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
About Us
Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.
Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.
Being a better ally at work
We’re always identifying ways to be better allies to one another at our family-owned company.
Emerging Talent
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Supplier Diversity
Supplier Diversity
Country Management Committee: A Message | Boehringer Ingelheim US
Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.
FDA approved treatment option for adults with CKD
The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.
Pushing for Progress
Pushing for Progress
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
Boehringer Ingelheim launches vaccine to protect poultry from three diseases
FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US
An FDA study found that PRADAXA was associated with reduced risks of ischemic stroke, intracranial hemorrhage & death. View ISI, PI & Med Guide.
Patient Assistance Program
BI Cares Patient Assistance Program Error
Full results from EMPERIAL exercise ability trials presented
Full results from EMPERIAL exercise ability trials presented
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
Talking drug discovery with our U.S. research site head, Carine Boustany
Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.
Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US
Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.